comparemela.com

Latest Breaking News On - Nasdaq cytk - Page 1 : comparemela.com

Fisher Asset Management LLC Makes New $44 75 Million Investment in Cytokinetics, Incorporated (NASDAQ:CYTK)

Fisher Asset Management LLC purchased a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 535,954 shares of the biopharmaceutical company’s stock, valued at approximately $44,747,000. Fisher Asset Management LLC owned approximately 0.55% of Cytokinetics […]

Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Rating of Moderate Buy from Brokerages

Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the fifteen ratings firms that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average twelve-month price objective […]

2,439 Shares in Cytokinetics, Incorporated (NASDAQ:CYTK) Purchased by Sage Rhino Capital LLC

Sage Rhino Capital LLC acquired a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,439 shares of the biopharmaceutical company’s stock, valued at approximately $204,000. Several other […]

Needham & Company LLC Reaffirms Buy Rating for Cytokinetics (NASDAQ:CYTK)

Needham & Company LLC reissued their buy rating on shares of Cytokinetics (NASDAQ:CYTK – Free Report) in a research report released on Tuesday morning, Benzinga reports. The firm currently has a $108.00 price objective on the biopharmaceutical company’s stock. Other equities analysts also recently issued reports about the company. Oppenheimer reiterated an outperform rating and […]

Cytokinetics, Incorporated (NASDAQ:CYTK) Given Consensus Rating of Moderate Buy by Analysts

Shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) have been given an average recommendation of “Moderate Buy” by the fifteen analysts that are presently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average twelve-month […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.